Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2000;95:104-110
© 2000 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by COHEN, F. J.
Right arrow Articles by PLOUFFE, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COHEN, F. J.
Right arrow Articles by PLOUFFE, L., Jr

ORIGINAL RESEARCH

Uterine Effects of 3-Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60

FREDRIC J. COHEN, MD, STEVEN WATTS, MS, AARTI SHAH, PhD, ROBIN AKERS and LEO PLOUFFE, Jr, MD

From the Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana.

Address reprint requests to: Fredric J. Cohen, MD, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285

Objective: To assess the uterine effects of 3 years of therapy with raloxifene in healthy, postmenopausal women under age 60.

Methods: Integrated data from two identically designed, randomized, double-masked, placebo-controlled clinical trials were analyzed. Nine hundred sixty-nine healthy women with uteri (ages 45 through 60, 2 to 8 years postmenopausal) were assigned randomly to raloxifene 30, 60, or 150 mg per day, or an identical placebo for 3 years. Endometrial thickness was evaluated with transvaginal ultrasonography every 6 months for 2 years and again after 3 years. Further uterine evaluation, including endometrial sampling if necessary, was initiated for vaginal bleeding or findings of endometrial thickness greater than 5 mm.

Results: Endometrial thickness was unchanged by raloxifene and not significantly different from placebo at any time. One hundred seventy-two women had at least one episode of endometrial thickness greater than 5 mm or vaginal bleeding distributed equally among all groups. A total of 102 (10.5%) women underwent endometrial sampling at least once: 15 (1.5%) for vaginal bleeding, 78 (8.0%) for endometrial thickness greater than 5 mm, and nine (0.9%) for other reasons. There were no significant treatment differences in the proportion of women sampled, in the clinical findings, or in the histologic diagnoses.

Conclusion: Raloxifene given to healthy postmenopausal women at doses from 30 to 150 mg per day does not stimulate uterine growth and does not cause vaginal bleeding, spotting, or discharge through 3 years of therapy. Thus, any bleeding during therapy should be deemed unexpected and prompt a clinical evaluation.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
L. E. Waetjen, J. S. Brown, E. Vittinghoff, K. E. Ensrud, J. Pinkerton, R. Wallace, J. L. Macer, D. Grady, and for the Ultra Low Dose Transdermal estRogen Assess
The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women
Obstet. Gynecol., November 1, 2005; 106(5): 946 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Carr, R. H. Knopp, J. D. Brunzell, B. S. Wheeler, X. Zhu, M. Lakshmanan, A. S. Rosen, and P. W. Anderson
Effect of Raloxifene on Serum Triglycerides in Women With a History of Hypertriglyceridemia While on Oral Estrogen Therapy
Diabetes Care, July 1, 2005; 28(7): 1555 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Phillips, A. J. Tyson-Capper (nee Pollard), J. Bailey, S. C. Robson, and G. N. Europe-Finner
Regulation of Expression of the Chorionic Gonadotropin/Luteinizing Hormone Receptor Gene in the Human Myometrium: Involvement of Specificity Protein-1 (Sp1), Sp3, Sp4, Sp-Like Proteins, and Histone Deacetylases
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3479 - 3490.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
L.M. Helvering, M.D. Adrian, A.G. Geiser, S.T. Estrem, T. Wei, S. Huang, P. Chen, E.R. Dow, J. N. Calley, J.A. Dodge, et al.
Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus
Biol Reprod, April 1, 2005; 72(4): 830 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
P. Neven, D. Quail, M. Levrier, F. Aguas, H. S. The, C. De Geyter, M. D. Glant, H. Beck, B. Bosio-LeGoux, H. Schmitt, et al.
Uterine Effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study
Obstet. Gynecol., May 1, 2004; 103(5): 881 - 891.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Martino, J. Costantino, M. McNabb, J. Mershon, K. Bryant, T. Powles, and R. J. Secrest
The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials
Oncologist, April 1, 2004; 9(2): 116 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
L. E. Waetjen, J. S. Brown, K. Modelska, T. Blackwell, E. Vittinghoff, and S. R. Cummings
Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial
Obstet. Gynecol., February 1, 2004; 103(2): 261 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
S. Gordon, B. W. Walsh, A. V. Ciaccia, S. Siddhanti, A. S. Rosen, and L. Plouffe Jr
Transition From Estrogen-Progestin to Raloxifene in Postmenopausal Women: Effect on Vasomotor Symptoms
Obstet. Gynecol., February 1, 2004; 103(2): 267 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Palomba, T. Russo, F. Orio Jr, L. Tauchmanova, E. Zupi, P. L. B. Panici, C. Nappi, A. Colao, G. Lombardi, and F. Zullo
Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial
Hum. Reprod., December 1, 2002; 17(12): 3213 - 3219.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo
Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, E. Zupi, G. Lombardi, C. Nappi, P. L. B. Panici, and F. Zullo
Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3603 - 3608.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Levenson, K. M. Svoboda, K. M. Pease, S. A. Kaiser, B. Chen, L. A. Simons, B. D. Jovanovic, P. A. Dyck, and V. C. Jordan
Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor
Cancer Res., August 1, 2002; 62(15): 4419 - 4426.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. M. O'Regan, C. Gajdos, R. C. Dardes, A. De Los Reyes, W. Park, A. W. Rademaker, and V. C. Jordan
Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice
J Natl Cancer Inst, February 20, 2002; 94(4): 274 - 283.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. C. Jordan, S. Gapstur, and M. Morrow
Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease
J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. Lorraine
Raloxifene and breast cancer
Can. Med. Assoc. J., October 1, 2001; 165(7): 888 - 888.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
V. C. Jordan
Selective Estrogen Receptor Modulation: A Personal Perspective
Cancer Res., August 1, 2001; 61(15): 5683 - 5687.
[Full Text] [PDF]

Home page
 Obstet GynecolHome page
S. R. Goldstein, P. Neven, L. Zhou, Y. L. Taylor, A. V. Ciaccia, and L. Plouffe Jr
Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation
Obstet. Gynecol., July 1, 2001; 98(1): 91 - 96.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Lippman, K. A. Krueger, S. Eckert, A. Sashegyi, E. L. Walls, S. Jamal, J. A. Cauley, and S. R. Cummings
Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants
J. Clin. Oncol., June 15, 2001; 19(12): 3111 - 3116.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. B. Muchmore
Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects
Oncologist, October 1, 2000; 5(5): 388 - 392.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. M. Klotz, S. C. Hewitt, K. S. Korach, and R. P. Diaugustine
Activation of a Uterine Insulin-Like Growth Factor I Signaling Pathway by Clinical and Environmental Estrogens: Requirement of Estrogen Receptor-{alpha}
Endocrinology, September 1, 2000; 141(9): 3430 - 3439.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Obstetricians and Gynecologists.